Introducing Yntradose;
a radiation source brought directly to tumours.

The most common form of radiotherapy, Stereotactic Body Radiotherapy (‘SBRT’) involves focussing external radiation into tumour(s) in the body. However, collateral damage is imparted to healthy tissue in the path of the beams and organ movement significantly limits the administered dose. More advanced Proton Beam Radiotherapy (‘PBRT’) greatly reduces collateral damage by employing proton beams of fixed penetration depth but still face the challenge of organ movement, however, its widespread adoption is heavily impaired by the cost of building treatment suites and low patient throughput. As such, these approaches are seldom used to treat abdominal organs such as the liver and pancreas.

Introducing YntraDose designed as a safe, easy-to-use, targeted and personalised radiotherapeutic treatment option for a wide range of solid tumour cancer anatomies and patient groups that overcomes the limitations of SBRT and PBRT whilst maximising the administered radiotherapeutic index for the patient in a single day case treatment session.

YntraDose consists of radioactive microspheres (that contain beta-radiating yttrium-90 (90Y)) and a biocompatible bioglue agent that, following injection, rapidly sets to form a polymerized matrix that retains the microspheres specifically at the site of injection. Depending on the clinical setting, YntraDose can either be percutaneously delivered directly to the tumour under radiological guidance or directly into a tumour bed following resection. Percutaneous administration is performed under local anaesthesia and conscious sedation by an interventional radiologist.